



DUANE MORRIS LLP
ONE LIBERTY PLACE
PHILADELPHIA, PA 19103-7396
PHONE: 215.979.1000
FAX: 215.979.1020

FAX RECEIVED

Aug 12 2002

GROUP 1600

FACSIMILE TRANSMITTAL SHEET

To: Examiner Anne L. Holleran, Art Unit 1642

FIRM/COMPANY: United States Patent and Trademark Office
Serial No. 09/839,779; Filing Date: 04/20/2001

FACSIMILE NUMBER: 703-308-2742

CONFIRMATION
TELEPHONE: 703-308-8892 or 703-308-0196

FROM: Melanie S. Goddard

DIRECT DIAL: 215.979.1310

DATE: August 12, 2002

USER NUMBER: 7443

FILE NUMBER: U0381-00001

TOTAL # OF PAGES: 3
(INCLUDING COVERSHEET)

MESSAGE: PLEASE DELIVER TO EXAMINER ANNE L. HOLLERAN
IMMEDIATELY.

PH1\10021651NOTE: Original will NOT follow.

CONFIDENTIALITY NOTICE

THIS FACSIMILE TRANSMISSION IS PRIVILEGED AND CONFIDENTIAL AND IS INTENDED ONLY FOR THE REVIEW OF THE PARTY TO WHOM IT IS ADDRESSED. IF YOU HAVE RECEIVED THIS TRANSMISSION IN ERROR, PLEASE IMMEDIATELY TELEPHONE THE SENDER ABOVE TO ARRANGE FOR ITS RETURN, AND IT SHALL NOT CONSTITUTE WAIVER OF THE ATTORNEY-CLIENT PRIVILEGE.

PATENT**Docket No. U0381-00001****FAX RECEIVED**

In re application of: Amin I. Kassis
Serial No.: 09/839,779

Filed: April 20, 2001

For: METHODS FOR TUMOR DIAGNOSIS
AND THERAPYExaminer: Anne L. Holleran
Group Art Unit: 1642

GROUP 1600

I, MELANIE S. GODDARD, REGISTRATION NO. 46,732 CERTIFY
THAT THIS CORRESPONDENCE IS BEING TRANSMITTED VIA
FACSIMILE TO THE UNITED STATES PATENT AND TRADEMARK
OFFICE:

ON 8/12/02


MELANIE S. GODDARD

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

RESPONSE TO RESTRICTION REQUIREMENT

This is in response to the restriction requirement in the Official Action dated July 16, 2002.

REMARKS

The Examiner requires election among the following sets of species:

I. The Examiner states that each enzyme recited in Claim 5 is a separate species. Claims 1-20 are said to be generic. Applicant provisionally elects the enzyme phosphatase, with traverse. Claims 1-20 read on this species.

II. The Examiner states that each targeting moiety listed in claim 8 is a separate species. Claims 1-8 and 12-20 are said to be generic. Applicant provisionally elects the targeting moiety is an antibody, with traverse. Claims 1-9 and 12-20 read on this species.

PATENT**Docket No. U0381-00001**

III. The Examiner states that the different recited examples for R¹ are separate species. Claims 1-14 and 20 are said to be generic. Applicant provisionally elects a gamma emitter, with traverse. Claims 1-15 and 20 read on this species.

IV. The Examiner states that the different recited examples for BLOCK are separate species. Claims 1-20 are said to be generic. Applicant elects the species wherein BLOCK is a monovalent blocking group derivable by removal of one hydroxyl from a phosphoric acid group, a sulfuric acid group, or a biologically compatible salt thereof, without traverse. Claims 1-20 read on this species.

With respect to the election requirement in I - III above, Applicants contend that in each case, such an election requirement is improper as the items or compounds in each group are not patentably distinct. M.P.E.P. § 806.05 states that "If [the inventions] are not distinct, restriction is never proper".

Applicants request modification of the election requirement as set forth above, in accordance with the M.P.E.P. Accordingly, examination of claims 1-20 is respectfully requested.

Respectfully submitted,

Dated: 8/12/02

Melanie S. Goddard
Melanie S. Goddard, Reg. No.: 46,732
Attorney For Applicants

DUANE, MORRIS LLP
One Liberty Place
Philadelphia, Pennsylvania 19103-7396
(215) 979-1310 (Telephone)
(215) 979-1020 (Fax)